C2N Diagnostics at CTAD 2026: Advancing Clinical Solutions in Alzheimer’s Disease
November 16–19 | Boston, Massachusetts
Join C2N Diagnostics in Boston for the Clinical Trials on Alzheimer’s Disease (CTAD) 2026 conference, November 16–19, as researchers and clinicians from around the world converge to share the latest advances in Alzheimer’s disease clinical care and research.
C2N is contributing to the scientific conversation with 6 sessions and 5 posters featuring research and clinical insights related to the Precivity® line of blood tests. These presentations highlight advances in blood biomarkers and their role in understanding Alzheimer’s disease, identifying amyloid pathology, and supporting the development of clinical trials.
Explore the presentations below and discover the latest research featuring C2N’s technology and scientific collaborations.
Connect with C2N in Boston
We invite you to meet with our team during CTAD to learn more about the Precivity® portfolio and our latest scientific developments.
All sessions and posters will be held at the Boston Marriott Copley Place.
Sessions Featuring C2N Data
6 scientific sessions will feature research and findings related to the Precivity® blood tests.
Tuesday, November 17
8:30 a.m.
Symposium 2 – CSF and Plasma Biomarker Changes After Anti-Tau Therapy: Fluid Biomarker Results from the Auτonomy Phase 2 Clinical Trial
10:20 a.m.
OC10 – Sex Differences in Plasma p-tau217, Amyloid-β, and Tau-PET in Cognitively Unimpaired Adults from the AHEAD International Screening Cohort
Wednesday, November 18
9:15 a.m.
OC22 – Estimating 15-Year Absolute Risk of Cognitive Impairment in Cognitively Unimpaired Older Adults with Alzheimer Disease Biomarkers Based on Amyloid PET or Plasma %p-tau217
1:55 p.m.
OC30 – LM11A-31 Reduces CSF Levels of eMTBR-tau243: A Retrospective Analysis of a Phase 2a Safety and Exploratory Biomarker Trial in Mild-Moderate Alzheimer’s Disease
2:25 p.m.
OC32 – Calibrated Age of Onset for Amyloid Positivity from Plasma %p-tau217 Leads to Better Design and Improved Representation of Black Americans in Alzheimer Disease Clinical Trials: Simpson’s Paradox
Thursday, November 19
3:35 p.m.
OC58 – Plasma %p-tau217 and Aβ42/Aβ40 Provide Complementary Information About Amyloid PET Below 20 Centiloids: Baseline Findings from the Alzheimer’s Plasma Extension Study
Posters Featuring C2N Data
5 scientific posters will showcase additional research involving C2N technology and scientific collaborations.
Tuesday, November 17
Clinical Trials – Phase IIb & III
P006
Plasma Biomarker Screening for Amyloid Status in the BenfoTeam Randomized Controlled Trial in Early Alzheimer’s Disease
P026
C2N Eligibility, APOE Genotype Identification, Amyloid Confirmation. Results from the AHEAD 3-45 Programme at Neuroclinx Glasgow
Wednesday, November 18
Biomarkers (CSF & Plasma)
P252
Performance of Plasma and CSF Biomarkers for Tau PET Staging in Alzheimer’s Disease: Evidence from Mass Spectrometry and Immunoassays in Autonomy
P278
Evaluation of Alzheimer’s Blood Based Biomarkers in Race, Sex, Education, FAST and APOE4 Carrier Status
P303
Distribution of Biomarkers Among Patients Meeting Clinical Criteria for Alzheimer’s Disease Psychosis Who Are Biomarker Negative for Amyloid Proteinopathy and p-Tau217
We look forward to seeing you in Boston!
Follow us on LinkedIn and stay up to date on the latest news and developments from C2N Diagnostics.
About C2N Diagnostics, LLC
C2N Diagnostics is a specialty diagnostics company with a vision to bring Clarity Through Innovation®. C2N strives to provide exceptional laboratory services and products in the field of brain health. C2N’s biomarker services and products are used for: clinical decision making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. For more information visit www.C2N.com.